Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 20/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19979487 | 0.94 | MEN1 (0.58) | MEN1KMT2A | |
| SCHEMBL19032370 | 0.89 | MEN1 (0.59) | MEN1KMT2A | |
| SCHEMBL19979483 | 0.89 | MEN1 (0.65) | MEN1KMT2A | |
| SCHEMBL19032309 | 0.89 | MEN1 (0.65) | MEN1KMT2A | |
| SCHEMBL19979214 | 0.89 | MEN1 (0.65) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL19032282 | 0.88 | MEN1 (0.64) | MEN1KMT2A | |
| SCHEMBL19979498 | 0.87 | MEN1 (0.64) | MEN1KMT2A | |
| SCHEMBL19032206 | 0.86 | MEN1 (0.59) | MEN1KMT2A | |
| SCHEMBL16031382 | 0.85 | MEN1 (0.69) | MEN1KMT2A | |
| SCHEMBL19687736 | 0.85 | MEN1 (0.68) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-3394064-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.